For Nexavar In Lung Cancer, Focus Moves From First To Second Line

Nexavar failed to meet the primary endpoint of a second Phase III trial in first-line lung cancer, but Bayer/Onyx remain optimistic about prospects for the drug in the disease based on biomarkers.